Oxford Biomedica plc (OXB) Ordinary 50p
Oxford BioMedica Plc is a gene and cell therapy company. The Company and its subsidiaries has developed lentiviral vector delivery platform (LentiVector), which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, liver and central nervous system (CNS) disorders. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401 and addresses neurodegenerative and a range of cancers. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.